PD-L1, IHC (Pembrolizumab) Gastric
Also known as: Keytruda®, Programmed Death Ligand 1
Use
The Dako PD-L1 22C3 pharmDx™ kit is a qualitative assay intended for use in the detection of PD-L1 in formalin-fixed, paraffin embedded (FFPE) in gastric carcinoma using the Dako Automated Link 48 Platform.
Special Instructions
Not provided.
Limitations
Slides sectioned more than a month prior to testing may result in inaccurate or invalid staining results. This test is specifically optimized for gastric carcinoma and may not be suitable for other tissue types without further validation. Tissue quality and preparation are crucial for the accuracy of immunohistochemical analysis.
Methodology
Immunoassay (IHC)
Biomarkers
PD-L1
Protein
LOINC Codes
- 83052-1 - PD-L1 by 22C3 Tiss Ql ImStn
- 83052-1 - PD-L1 by 22C3 Tiss Ql ImStn
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
At least three positively charged, unstained slides should be sectioned at 4-5 microns and be less than one month in age.
Minimum Volume
Not provided
Container
Paraffin block or unstained positive-charged slides
Collection Instructions
Paraffin block or unstained slides sectioned of no more than one month age.
Storage Instructions
FFPE tissue specimens must be handled to preserve the tissue for IHC staining. Standard methods of tissue processing should be used for all specimens.
Causes for Rejection
Slides cut 5 months or more prior to testing
Other tests from different labs that may be relevant